Aquaporin-4 (AQP4) Antibody, IgG by CBA-IFA With Reflex to Titer, CSF
Ordering Recommendation
Useful in the initial evaluation of neuromyelitis optica (NMO) spectrum disorders. This test uses a cell-based assay (CBA) to detect antibodies against aquaporin-4.
New York DOH Approval Status
Specimen Required
CSF.
Transfer 0.5 mL CSF to an ARUP standard transport tube. (Min: 0.15 mL)
Refrigerated.
Hemolyzed, contaminated specimens or severely lipemic specimens.
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
Methodology
Semi-Quantitative Cell-Based Indirect Fluorescent Antibody
Performed
Mon, Wed, Fri
Reported
1-6 days
Reference Interval
Less than 1:1
Interpretive Data
Neuromyelitis optic (NMO) commonly presents with optic neuritis or longitudinally extensive transverse myelitis. Approximately 75% of patients with NMO have antibodies to the aquaporin-4 (AQP4) receptor. While the absence of AQP4 receptor antibodies does not rule out a diagnosis of NMO, presence of this antibody is diagnostic for NMO.
This indirect fluorescent antibody assay utilizes AQP4 receptor transfected cell lines for the detection and semiquantification of AQP4 IgG antibody.
Laboratory Developed Test (LDT)
Note
If AQP4 antibody IgG is positive, then an AQP4 antibody IgG titer is reported. Additional charges apply.
Hotline History
Hotline History
CPT Codes
86052; if reflexed, add 86256
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
2011700 | NMO/AQP4 Ab IgG CBA-IFA Screen, CSF | 46718-3 |
Aliases
- AQP
- AQP4
- AQP4 antibody
- Aquaporin; Devic's Ab
- Cell-based assay
- Cell-binding assay
- CNS demyelinating disease
- Devic's Antibody
- Myelopathy
- Neuromyelitis Optica (NMO) Antibody
- Neuromyelitis Optica IgG
- NMO-IgG
- NMOSD
- Optic Neuritis Ab
- Optic Neuritis Antibody
- Optic-Spinal MS Antibody
- Pediatric CNS disorders
- Soft-NMOS
- Transverse Myelitis Ab
- Vision Loss Ab